Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1741029 | 0.85 | NPC1 (0.64) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23850102 | 0.83 | NPC1 (0.50) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31429362 | 0.81 | NPC1 (0.46) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL31573749 | 0.81 | NPC1 (0.46) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL859427 | 0.81 | KDM4E (0.49) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3454821 | 0.81 | NPC1 (0.68) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL30133847 | 0.81 | NPC1 (0.68) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL12764246 | 0.81 | NPC1 (0.48) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19256696 | 0.80 | NPC1 (0.48) | NPC1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL29342011 | 0.80 | ALDH1A1 (0.49) | NPC1ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | PFIZER INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4471029-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | Suzhou Genhouse Bio Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | SUZHOU GENHOUSE BIO CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| CN-118541371-A | Methionine adenosyltransferase 2A inhibitors for the treatment of MTAP deleted cancers | 勤浩医药（苏州）有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9040538-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITE LAVAL (CA) | 2015-05-26 | — | — | US | disclosed |
| EP-2432776-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | Chlorion Pharma, Inc. (CA) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | NPC1 2501/4885ALDH1A1 577/4885KDM4E 3841/4885 |
| US-20250188030-A1 | Biphenyl and Phenylpyridine Compounds | CYP1B1, CYP1A1, PAH | NPC1 388/4885ALDH1A1 39/4885KDM4E 364/4885 |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | NPC1 2501/4885ALDH1A1 577/4885KDM4E 3841/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | NPC1 1644/4885ALDH1A1 1916/4885KDM4E 2475/4885 |
| US-20260028316-A1 | Biphenyl and Phenylpyridine Compounds | KAT2B, KAT2A, KAT6A | NPC1 2011/4885ALDH1A1 1348/4885KDM4E 57/4885 |
| US-20240391923-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER | MAT2B, MAT2A, MAT1A | NPC1 3299/4885ALDH1A1 641/4885KDM4E 787/4885 |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | NPC1 185/4885ALDH1A1 2748/4885KDM4E 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.